{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:45:14Z","timestamp":1793335514245,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jhep.2024.08.031","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T20:13:22Z","timestamp":1727208802000},"page":"438-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH"],"prefix":"10.1016","volume":"82","author":[{"given":"Naim","family":"Alkhouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4120-2788","authenticated-orcid":false,"given":"Cayden","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-2063","authenticated-orcid":false,"given":"Elizabeth","family":"Shumbayawonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneli","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-1626","authenticated-orcid":false,"given":"Kitty","family":"Yale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-6903","authenticated-orcid":false,"given":"Timothy","family":"Rolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7587-718X","authenticated-orcid":false,"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-1577","authenticated-orcid":false,"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-418X","authenticated-orcid":false,"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5610-3266","authenticated-orcid":false,"given":"Michele","family":"Pansini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0152-6528","authenticated-orcid":false,"given":"Andrea","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.08.031_bib1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.08.031_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib3","article-title":"Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","author":"Younossi","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.08.031_bib4","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.08.031_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cld.1006","article-title":"Molecular mechanisms linking nonalcoholic steatohepatitis to cancer","volume":"17","author":"Wegermann","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2024.08.031_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/liv.13302","article-title":"Therapies in non-alcoholic steatohepatitis (NASH)","volume":"37","author":"Oseini","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.08.031_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib8","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.08.031_bib9","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.08.031_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A\u00a0randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.08.031_bib11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.08.031_bib12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.08.031_bib13","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1007\/s10620-021-07089-w","article-title":"Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis","volume":"67","author":"Thomaides-Brears","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2024.08.031_bib14","first-page":"2920","article-title":"Non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) using ultrasound image echogenicity","volume":"2017","author":"Benjamin","year":"2017","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"key":"10.1016\/j.jhep.2024.08.031_bib15","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.08.031_bib16","first-page":"1456","article-title":"Nonalcoholic steatohepatitis with compensated cirrhosis: developing drugs for treatment guidance for industry nonalcoholic steatohepatitis with compensated cirrhosis: developing drugs for treatment guidance for industry","volume":"49","year":"2019","journal-title":"Draft Guidance"},{"key":"10.1016\/j.jhep.2024.08.031_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/1756283X16656735","article-title":"Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis","volume":"9","author":"Patel","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2024.08.031_bib18","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib19","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0168-8278(20)31347-7","article-title":"Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the REGENERATE trial - AS075","volume":"73","author":"Loomba","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","volume":"71","author":"Tamaki","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.08.031_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.09090769","article-title":"Presence of coronary plaques in patients with nonalcoholic fatty liver disease","volume":"254","author":"Assy","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2024.08.031_bib22","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2214\/AJR.13.11367","article-title":"Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications","volume":"202","author":"Pickhardt","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhep.2024.08.031_bib23","article-title":"Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality","author":"Lee","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.08.031_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jhep.2024.08.031_bib25","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/ckj\/sfac054","article-title":"Multiparametric magnetic resonance imaging allows non-invasive functional and structural evaluation of diabetic kidney disease","volume":"15","author":"Makvandi","year":"2022","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.jhep.2024.08.031_bib26","article-title":"Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease","volume":"1","author":"Mak","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.08.031_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1118\/1.595535","article-title":"A\u00a0review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age","volume":"11","author":"Bottomley","year":"1984","journal-title":"Med Phys"},{"key":"10.1016\/j.jhep.2024.08.031_bib28","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1007\/s00330-023-10067-7","article-title":"A\u00a0better understanding of liver T1","volume":"33","author":"Hernando","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2024.08.031_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1532-429X-16-2","article-title":"T1-mapping in the heart: accuracy and precision","volume":"16","author":"Kellman","year":"2014","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jhep.2024.08.031_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.4530","article-title":"Hydration and glycogen affect T1 relaxation times of liver tissue","volume":"34","author":"M\u00f3zes","year":"2021","journal-title":"NMR Biomed"},{"key":"10.1016\/j.jhep.2024.08.031_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jmri.25146","article-title":"Influence of fat on liver T1 measurements using modified Look-Locker inversion recovery (MOLLI) methods at 3T","volume":"44","author":"Mozes","year":"2016","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jhep.2024.08.031_bib32","article-title":"Prognostic value of hepatic native T1 and extracellular volume fraction in patients with pulmonary arterial hypertension","volume":"11","author":"Guo","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jhep.2024.08.031_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jmri.25392","article-title":"A\u00a0model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look-Locker inversion recovery T1 (shMOLLI-T1 ) in the liver","volume":"45","author":"Tunnicliffe","year":"2017","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jhep.2024.08.031_bib34","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/nbm.3299","article-title":"A\u00a0study of T\u2081 relaxation time as a measure of liver fibrosis and the influence of confounding histological factors","volume":"28","author":"Hoad","year":"2015","journal-title":"NMR Biomed"},{"key":"10.1016\/j.jhep.2024.08.031_bib35","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/jmri.28906","article-title":"An empirical approach to derive water T1 from multiparametric MR images using an automated pipeline and comparison with liver stiffness","volume":"59","author":"Michelotti","year":"2024","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jhep.2024.08.031_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94754-9","article-title":"Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease","volume":"11","author":"Janowski","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.08.031_bib37","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep4.1687","article-title":"Multiparametric magnetic resonance imaging, autoimmune hepatitis, and prediction of disease activity","volume":"5","author":"Arndtz","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.08.031_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101325","article-title":"Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis","volume":"46","author":"Heneghan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2024.08.031_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpb.2024.02.008","article-title":"Novel multiparametric MRI detects improved future liver remnant quality post-dual vein embolization","author":"Sundaravadanan","year":"2024","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2024.08.031_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/LVT.0000000000000450","article-title":"MRI-serum-based score accurately identifies liver transplant patients without rejection avoiding need for liver biopsy: a multisite European study","author":"Schaapman","year":"2024","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2024.08.031_bib41","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","article-title":"Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease","volume":"60","author":"Banerjee","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib43","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/liv.13284","article-title":"Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity","volume":"37","author":"Pavlides","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.08.031_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71995-8","article-title":"A\u00a0composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis","volume":"10","author":"Dennis","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.08.031_bib45","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/liv.14625","article-title":"Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease","volume":"40","author":"Jayaswal","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.08.031_bib46","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","article-title":"Liver disease is a significant risk factor for cardiovascular outcomes - a UK Biobank study","volume":"79","author":"Roca-Fernandez","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib47","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.08.031_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30763-7","article-title":"Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"S1","key":"10.1016\/j.jhep.2024.08.031_bib49","first-page":"1875","article-title":"Liver-distributed FXR agonist TERN-101 leads to corrected T1 (cT1) response and a population shift to lower cT1 risk categories in NASH phase 2a LIFT study","volume":"74","author":"Lawitz","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4228321","article-title":"Multiparametric magnetic resonance imaging and magnetic resonance elastography to evaluate the early effects of bariatric surgery on nonalcoholic fatty liver disease","volume":"2023","author":"Tan","year":"2023","journal-title":"Int J Biomed Imaging"},{"key":"10.1016\/j.jhep.2024.08.031_bib51","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/oby.23793","article-title":"A\u00a0low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis","volume":"31","author":"Koutoukidis","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2024.08.031_bib52","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","author":"Loomba","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.08.031_bib53","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.14309\/ajg.0000000000001375","article-title":"Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease","volume":"116","author":"Harrison","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.08.031_bib54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib55","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 Weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.08.031_bib56","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.08.031_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.575843","article-title":"Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis","volume":"11","author":"Dennis","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jhep.2024.08.031_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214921","article-title":"Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver","volume":"14","author":"Bachtiar","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.08.031_bib59","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30418","volume":"70","author":"Brunt","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.08.031_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A\u00a0phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.08.031_bib61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2036.2012.05121.x","article-title":"Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD","volume":"36","author":"Permutt","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.08.031_bib62","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1053\/j.gastro.2018.07.018","article-title":"Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis","volume":"155","author":"Wildman-Tobriner","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824025595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824025595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T16:37:40Z","timestamp":1739551060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824025595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0168827824025595"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.08.031","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}